Title |
HMG CoA reductase inhibitors (statins) for dialysis patients
|
---|---|
Published in |
Cochrane database of systematic reviews, September 2013
|
DOI | 10.1002/14651858.cd004289.pub5 |
Pubmed ID | |
Authors |
Suetonia C Palmer, Sankar D Navaneethan, Jonathan C Craig, David W Johnson, Vlado Perkovic, Sagar U Nigwekar, Jorgen Hegbrant, Giovanni FM Strippoli |
Abstract |
People with advanced kidney disease treated with dialysis experience mortality rates from cardiovascular disease that are substantially higher than for the general population. Studies that have assessed the benefits of statins (HMG CoA reductase inhibitors) report conflicting conclusions for people on dialysis and existing meta-analyses have not had sufficient power to determine whether the effects of statins vary with severity of kidney disease. Recently, additional data for the effects of statins in dialysis patients have become available. This is an update of a review first published in 2004 and last updated in 2009. |
Twitter Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Australia | 4 | 17% |
Spain | 3 | 13% |
Canada | 2 | 8% |
Nigeria | 1 | 4% |
Saudi Arabia | 1 | 4% |
United Kingdom | 1 | 4% |
Colombia | 1 | 4% |
Netherlands | 1 | 4% |
Unknown | 10 | 42% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 17 | 71% |
Scientists | 4 | 17% |
Practitioners (doctors, other healthcare professionals) | 2 | 8% |
Science communicators (journalists, bloggers, editors) | 1 | 4% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | <1% |
India | 1 | <1% |
Australia | 1 | <1% |
Unknown | 218 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 37 | 17% |
Student > Bachelor | 28 | 13% |
Researcher | 18 | 8% |
Student > Postgraduate | 17 | 8% |
Other | 16 | 7% |
Other | 50 | 23% |
Unknown | 55 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 99 | 45% |
Nursing and Health Professions | 19 | 9% |
Pharmacology, Toxicology and Pharmaceutical Science | 8 | 4% |
Agricultural and Biological Sciences | 6 | 3% |
Psychology | 6 | 3% |
Other | 19 | 9% |
Unknown | 64 | 29% |